Is Wegovy Approved for Long-Term Weight Loss?
Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight with weight-related conditions, and in kids 12+ with obesity. Approval covers ongoing use beyond 1 year, based on trials showing sustained weight loss with continued dosing.[1][2]
How Long Have Patients Used It Safely?
In the STEP trials, participants used Wegovy for up to 2 years, losing 15-17% body weight on average versus 2-3% on placebo. Extension studies followed some for 4 years, with weight loss holding steady (around 10-11% from baseline) when doses stayed at 2.4 mg weekly. No new safety signals emerged beyond known risks like gallbladder issues.[3][4]
What Do Real-World Studies Show for Years-Long Use?
Post-approval data from over 2 years tracks thousands: weight regain averages 1-2 kg/year if doses drop or stop, but stabilizes with adherence. A 3-year Danish registry found 70% retention at 2.5 years, with cardiovascular benefits in high-risk patients. Long-term adherence hovers at 50-60% due to side effects or cost.[5][6]
What Happens If You Stop Wegovy?
Most users regain two-thirds of lost weight within a year off the drug, per STEP 1 extension data. Muscle loss during treatment (up to 40% of total weight shed) persists without lifestyle changes. Tapering doesn't fully prevent rebound.[7]
Common Long-Term Side Effects
GI issues (nausea, diarrhea) hit 40-50% initially but drop to 10-20% after 6 months. Rare risks include pancreatitis (0.2%), gastroparesis, and thyroid tumors in rodents (not confirmed in humans). Bone density and kidney concerns are monitored but not proven causal long-term. Annual monitoring advised.[8][9]
Who Should Avoid Long-Term Use?
Not for those with medullary thyroid cancer history, multiple endocrine neoplasia type 2, or severe GI disease. Pregnancy requires stopping 2 months prior. Cost ($1,300+/month without insurance) and weekly injections limit access; shortages persist.[10]
Alternatives for Lifelong Weight Control
| Option | Duration Approved | Weight Loss Edge | Key Drawback |
|--------|-------------------|------------------|--------------|
| Zepbound (tirzepatide) | Chronic | 20-22% (beats Wegovy) | Similar GI risks, newer data |
| Saxenda (liraglutide) | Chronic | 5-10% | Daily shots, less potent |
| Phentermine-topiramate (Qsymia) | Long-term | 8-10% | Addiction risk, daily pill |
| Bariatric surgery | Permanent | 25-30% | Invasive, irreversible |
Lifestyle alone sustains 5-10% loss in motivated groups, but <20% keep it 5+ years without meds.[11]
Cost and Access for Ongoing Treatment
$1,350/month list price; copays as low as $0-25 with Novo savings cards (income-qualified). Patents hold until 2030-2032; biosimilars unlikely before then. Check DrugPatentWatch.com for expiry details.[12][13]
Sources
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[2] Novo Nordisk Prescribing Info
[3] NEJM STEP 1 (2021): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[4] STEP 5 (2-year): https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[5] JAMA SELECT (real-world): https://jamanetwork.com/journals/jama/fullarticle/2812936
[6] Danish registry (2024)
[7] STEP 1 Extension: https://pubmed.ncbi.nlm.nih.gov/35441470/
[8] FDA Postmarketing Surveillance
[9] Lancet Diabetes (2023 review)
[10] Wegovy Warnings
[11] SURMOUNT-1 (Zepbound): NEJM 2022
[12] Novo Nordisk Pricing
[13] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/WEGOVY